tiprankstipranks
Advertisement
Advertisement

INCY Stock Latest News

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
The FlyIncyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
1d ago
INCY
MIRM
Incyte Advances Early-Stage Skin Drug Study, Supporting Long-Term Growth Story
PremiumCompany Announcements
Incyte Advances Early-Stage Skin Drug Study, Supporting Long-Term Growth Story
2d ago
INCY
Incyte Buy Rating Reiterated as Analyst Highlights Robust Pipeline, Clinical Catalysts and Maintains $124 Price Target
PremiumRatings
Incyte Buy Rating Reiterated as Analyst Highlights Robust Pipeline, Clinical Catalysts and Maintains $124 Price Target
4d ago
INCY
Incyte Buy Rating Reiterated as Monjuvi Data Support Diversification; $135 Price Target Maintained
PremiumRatings
Incyte Buy Rating Reiterated as Monjuvi Data Support Diversification; $135 Price Target Maintained
4d ago
INCY
Incyte announces results from Phase 3 frontMIND trial on tafasitamab
PremiumThe Fly
Incyte announces results from Phase 3 frontMIND trial on tafasitamab
5d ago
INCY
Wedbush bullish on Damora Therapeutics, initiates with an Outperform
PremiumThe FlyWedbush bullish on Damora Therapeutics, initiates with an Outperform
8d ago
DMRA
INCY
Incyte’s Ruxolitinib Cream Delivers Strong Phase 3b Eczema Data, Supporting Dermatology Upside for INCY
Premium
Company Announcements
Incyte’s Ruxolitinib Cream Delivers Strong Phase 3b Eczema Data, Supporting Dermatology Upside for INCY
14d ago
INCY
Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound
Premium
The Fly
Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound
15d ago
INCY
Incyte initiated with a Market Perform at Bernstein
PremiumThe Fly
Incyte initiated with a Market Perform at Bernstein
15d ago
INCY
Incyte, Genesis Molecular AI announce expansion of collaboration
PremiumThe Fly
Incyte, Genesis Molecular AI announce expansion of collaboration
16d ago
INCY
Incyte, Edison Scientific announce strategic collaboration to employ Kosmos
PremiumThe Fly
Incyte, Edison Scientific announce strategic collaboration to employ Kosmos
17d ago
INCY
Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
PremiumCompany Announcements
Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
28d ago
INCY
Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
PremiumThe FlyIncyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
29d ago
INCY
Incyte gets orphan designation for treatment of pancreatic cancer
Premium
The Fly
Incyte gets orphan designation for treatment of pancreatic cancer
1M ago
INCY
MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement
Premium
The Fly
MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement
1M ago
INCY
MGNX
Incyte announces FDA approval of Jakari XR
PremiumThe Fly
Incyte announces FDA approval of Jakari XR
1M ago
INCY
Incyte price target raised to $90 from $84 at Oppenheimer
PremiumThe Fly
Incyte price target raised to $90 from $84 at Oppenheimer
1M ago
INCY
Incyte price target raised to $123 from $120 at Stifel
PremiumThe Fly
Incyte price target raised to $123 from $120 at Stifel
1M ago
INCY
Incyte price target raised to $124 from $121 at BofA
PremiumThe Fly
Incyte price target raised to $124 from $121 at BofA
1M ago
INCY
Incyte: Buy Rating Reaffirmed as Pipeline Strength and Long-Term Visibility Drive Price Target Increase to $124
PremiumRatingsIncyte: Buy Rating Reaffirmed as Pipeline Strength and Long-Term Visibility Drive Price Target Increase to $124
1M ago
INCY
Incyte Earnings Call Highlights Broad Growth, Rising Risks
Premium
Company Announcements
Incyte Earnings Call Highlights Broad Growth, Rising Risks
1M ago
INCY
Incyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B
Premium
The Fly
Incyte sees FY26 revenue $4.77B-$4.94B, consensus $5.57B
1M ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >